Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis

British Journal of Ophthalmology

Volumn 93, Issue 7, 2009, Pages 906-913

  Deuter, C M E ^a   Kotter I ^b   Gunaydin I ^b   Stubiger N ^a   Doycheva, D G ^a   Zierhut, M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALPHA2A INTERFERON; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DEPRESSION; DISABILITY; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON-ALPHA; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 67649647396     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.153874     Document Type: Article

References (13)

1. Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113:1446-1449 (Pubitemid 44108170)
2. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm 2003;11:29-38. (Pubitemid 36918643)
3. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 2002;10:239-246 (Pubitemid 36886366)
4. Zierhut M, Thiel HJ, Schlote T. Treatment of uveitic macular edema with acetazolamide. Doc Ophthalmol 1999;97:409-413 (Pubitemid 30410114)
5. Kötter I, Stübiger N, Zierhut M. Use of interferon-α in Behçet's disease. In: Zierhut M, Ohno S, eds. Immunology of Behçet's disease. Lisse, Netherlands: Sewts & Zeitlinger, 2003:155-159
6. Kötter I, Günaydin I, Zierhut M, et al. The use of interferon α in Behçet disease: Review of the literature. Semin Arthritis Rheum 2004;33:320-335 (Pubitemid 38496041)
7. Deuter CME, Kötter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Ret Eye Res 2008;27:111-136
8. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-339 (Pubitemid 46586530)
9. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61. (Pubitemid 46963200)
10. Koetter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-431 (Pubitemid 36399030)
11. Deuter CME, Kötter I, Günaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006;26:786-791 (Pubitemid 44386101)
12. Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516 (Pubitemid 41224845)
13. Gillies MC, Su T. Interferon alpha-2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res 1995;49:277-288